排序方式: 共有2条查询结果,搜索用时 0 毫秒
1
1.
Papapoulos S. E.; Berg H. v.d.; Frolich M.; Valentijn R. M. 《Nephrology, dialysis, transplantation》1988,3(5):647-650
The formation of 1.25-dihydroxycholecalciferol (1.25-(OH)2D3after single intravenous injections of 1-hydroxycholecalciferol(1-OHD3) was examined in four patients with chronic renal failureon regular haemodialysis. Following 13µg 1-OHD3administered at weekly intervals, 1.25-(OH)2D3 appeared in thecirculation within 1 h, and peak concentrations were reachedbetween 2 h and 5 h. By 8 h serum 1.25-(OH)2D3 concentrationshad started declining and by 44 h they had returned to baselineafter 1µg 1-OHD3 but they were still above basal after2 and 3 µg by an average of 30 pmol/l. One week afterinjections, concentrations were back to basal in all patientsstudied. The serum 1,25-(OH)2D3 dose response to injected la-OHDwas linear, indicating ample capacity of the liver 25-hydroxylaseto further hydroxylate 1-OHD. However, examination of the individualresponses revealed lower increments in serum 1.25-(OH)3 concentrationsin the patients with the highest basal serum 25-hydroxyvitaminD concen trations. Intravenous 1-OHD3 may be useful in the furtherstudy of the interactions between 1.25-(OH)23 calcium and PTHin chronic renal failure, as well as of the hepatic metabolismof vitamin D. 相似文献
2.
钙与阿法骨化醇对老年男性骨质疏松患者骨密度及骨代谢的影响 总被引:8,自引:0,他引:8
目的:探讨钙与阿法骨化醇治疗老年男性骨质疏松患者的疗效及安全性。方法:原发性骨质疏松男性患者80例,随机分成对照组和治疗组,每组40例。对照组每天口服钙剂1片(钙尔奇D,每片含元素钙600 mg,含维生素D 125 U);治疗组每天在口服钙剂1片的同时,加服阿法骨化醇0.5 μg,连续治疗12个月。在治疗前、治疗后12个月分别测量腰椎(L2~4)及股骨颈骨密度(BMD)、骨代谢指标——骨钙素(BGP)、I型胶原C端异构肽(β CTX)、血钙、血磷、肝肾功能等。结果:治疗12个月后,治疗组在腰椎侧位BMD、股骨颈BMD较治疗前均明显增加(P<0.01),血清BGP增高明显(P<0.01),β CTX下降明显(P<0.01);对照组腰椎L2 4侧位BMD无明显变化(P>0.05),股骨颈BMD有明显下降(P<0.01),血清BGP无明显改变(P>0.05),β CTX增高显著(P<0.05)。两组肝肾功能,血、尿常规治疗前后差异无显著性(P>0.05)。结论:钙加阿法骨化醇可预防和治疗老年男性骨质疏松,疗效显著,而单纯补钙并不能安全预防骨量的丢失。 相似文献
1